Abstracts tagged "radiography"

Abstract Number: 1487 • ACR Convergence 2020
Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Analyses: Data from the Osteoarthritis Initiative
Amanda Nelson¹, Thomas Keefe², Todd Schwartz³, Richard Loeser¹, Yvonne Golightly⁴, Liubov Arbeeva¹ and J Marron², ¹University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Dept of Biostatistics, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill Dept of Epidemiology, Chapel Hill, NC
Background/Purpose: To utilize novel methodologies to explore subgroups within the OAI clinical data.Methods: From the OAI baseline dataset (n=4796 individuals with or at risk of…
Abstract Number: 1644 • ACR Convergence 2020
Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis
Ali Guermazi¹, Frank Roemer², Andrew Kompel¹, Luis Diaz³, Michel Crema⁴, Mark Brown⁵, Anne Hickman⁵, Glenn Pixton⁶, Lars Viktrup⁷, Robert Fountaine⁵, Aimee Burr⁵, Sarah Sherlock⁵ and Christine West⁸, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Boston Veteran Affairs Healthcare System, Boston, MA, ⁴Boston University School of Medicine, Paris, France, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc., Morrisville, NC, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tanezumab is a nerve growth factor monoclonal antibody in development for osteoarthritis (OA). Following a clinical hold due to concerns around adverse joint events,…
Abstract Number: 568 • 2019 ACR/ARP Annual Meeting
Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Farhan Syed¹, Kassel Fotinos-Hoyer ², Michael O'Connor ³, Maureen Li ³, Bryan Hermannsson ², Nicholas Enus ³, Sayali Karve ³, Manish Sharma ⁴, Gabriele Pradella ³, Robert B.M. Landewé ⁵, Xenofon Baraliakos ⁶ and Sarah Warner ³, ¹Parexel, Billerica, MA, ²Parexel, Berlin, Germany, ³Parexel, Billerica, ⁴Parexel, Hyderabad, India, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is typically radiographically confirmed on the sacroiliac joint (SIJ) as assessed by the modified New York (mNY) criteria. In clinical trials,…
Abstract Number: 618 • 2019 ACR/ARP Annual Meeting
Factors Associated with Complete Spinal Fusion in Patients with Ankylosing Spondylitis
Yasmin Maldonado¹, Michael Weisman ², Lianne Gensler ³, Michael Ward ⁴, Matthew Brown ⁵, MinJae Lee ⁶, Mark Hwang ⁶, Mariko Ishimori ⁷, Amirali Tahanan ⁶, Tom Learch ⁷, Mohammad Rahbar ⁶ and John Reveille ⁸, ¹The University of Texas-McGovern Medical School, Houston, TX, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University San Francisco California, San Francisco, CA, ⁴NIAMS, Bethesda, MD, ⁵Queensland University of Technology, Queensland, Australia, ⁶University of Texas-McGovern Medical School, Houston, TX, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸University of Texas McGovern Medical School, Houston
Background/Purpose: Most patients with ankylosing spondylitis (AS) do not develop complete spinal fusion. The purpose of this study was to compare patients with complete spinal…
Abstract Number: 938 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity
Alexandre Sepriano¹, Sofia Ramiro ², Stephanie Wichuk ³, Praveena Chiowchanwisawakit ⁴, Terrie MacCosham ³, Joel Paschke ⁵, Désirée van der Heijde ¹, Robert B.M. Landewé ⁶ and Walter Maksymowych ⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³University of Alberta, Edmonton, Canada, ⁴Mahidol University, Bangkok, Thailand, ⁵CARE Arthritis, Edmonton, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷University of Alberta and CARE Arthritis, Edmonton, Canada
Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…
Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
Philip Mease¹, Robert B.M. Landewé ², Proton Rahman ³, Hasan Tahir ⁴, Atul Singhal ⁵, Elke Böttcher ⁶, Sandra Navarra ⁷, Aimee Readie ⁸, Shephard Mpofu ⁹, Evie Maria Delicha ⁹, Luminita Pricop ⁸ and Désirée van der Heijde ¹⁰, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Southwest Rheumatology, Dallas, TX, ⁶Rheumazentrum Favoriten, Vienna, Austria, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
Abstract Number: 2185 • 2019 ACR/ARP Annual Meeting
MRI-detected Abnormalities in Prediction Models of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up
C. Kent Kwoh¹, Frank Roemer ², Erin Ashbeck ³, ChengCheng Hu ¹, Edward Bedrick ¹, Leena Sharma ⁴ and Ali Guermazi ⁵, ¹University of Arizona, Tucson, AZ, ²University of Erlangen-Nuremberg, Erlangen, Germany, ³The University of Arizona Arthritis Center, University of Arizona, Tuccson, AZ, Tucson, AL, ⁴Northwestern University, Chicago, IL, ⁵Boston Medical Center, Boston
Background/Purpose: MRI Osteoarthritis Knee Score (MOAKS) is a semi-quantitative scoring system used to assess MRI-detected structural abnormalities including over 100 raw scores representing multiple joint…
Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Peter M. ten Klooster^1,2, Laura M.M. Steunebrink³, Letty Versteeg⁴, Inmaculada de la Torre⁵, Francesco de Leonardis⁶, Walid Fakhouri⁶, Liliana Zaremba-Pechmann⁶ and Mart van de Laar^1,3, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ³Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
Abstract Number: 561 • 2018 ACR/ARHP Annual Meeting
U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Maxime MA Verhoeven¹, Maria JH de Hair², Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Xavier M Teitsma², Jacob van Laar², Floris PJG Lafeber², Johannes W. J. Bijlsma⁵ and Johannes W. G. Jacobs⁶, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Roche Nederland BV, Woerden, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The U-Act-Early trial was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission, with step-up…
Abstract Number: 1443 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Criteria for the Diagnosis of Erosive Rheumatoid Arthritis Disease Using Osteoarthritic Patients As Controls Compared to Validated Radiographic Criteria
Camille Roux¹, Frédérique Gandjbakhch², Audrey Pierreisnard³, Marion Couderc⁴, Cédric Lukas⁵, Racha Masri¹, Jean-Philippe Sommier¹, Isabelle Clerc-Urmès⁶, Cedric Baumann⁷, Isabelle Chary-Valckenaere⁸ and Damien Loeuille⁹, ¹Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ²UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ³APHP, Paris, France, ⁴Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Rheumatology, Lapeyronie Hospital and EA2415 Montpellier University, Montpellier, France, ⁶CHRU Nancy, Nancy, France, ⁷CHRU Nancy, Vandoeuvre les Nancy, France, ⁸Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France, ⁹Rheumatology, University Hospital of Nancy, NANCY, France
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease (1,2) responsible for structural damage. Radiography (RX) is considered as the gold standard…
Abstract Number: 1444 • 2018 ACR/ARHP Annual Meeting
Optimization of Ultrasonographic Examination for the Diagnosis of Erosive Rheumatoid Arthritis Versus Erosive Osteoarthritis with Radiography Considered As Gold Standard
Camille Roux¹, Frédérique Gandjbakhch², Audrey Pierreisnard³, Marion Couderc⁴, Cédric Lukas⁵, Racha Masri¹, Jean-Philippe Sommier¹, Isabelle Clerc-Urmès⁶, Cedric Baumann⁷, Isabelle Chary-Valckenaere⁸ and Damien Loeuille¹, ¹Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ²UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ³APHP, Paris, France, ⁴Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁶CHRU Nancy, Nancy, France, ⁷CHRU Nancy, Vandoeuvre les Nancy, France, ⁸Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease (1,2) responsible for structural damage. Radiography (RX) is considered as the gold standard…
Abstract Number: 533 • 2017 ACR/ARHP Annual Meeting
Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
Désirée van der Heijde¹, Jürgen Wollenhaupt², Stanley B Cohen³, Sander Strengholt⁴, Ketti Terry⁵, Ryan DeMasi⁶, Kenneth Kwok⁷, Irina Lazariciu⁸ and Lisy Wang⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸QuintilesIMS, Saint-Laurent, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The long-term safety and clinical efficacy of tofacitinib 5 and 10 mg…
Abstract Number: 1366 • 2017 ACR/ARHP Annual Meeting
Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients
Nevin Hammam^1,2, Shaimaa Salah³, Anthony Marotta⁴ and Emad F. Kholef⁵, ¹Rheumatology and Rehabilitation Department, University of Assiut, Assiut, Egypt, ²University of Alberta, Edmonton, AB, Canada, ³Rheumatology, Rehabilitation and Physical Medicine department, Faculty of Medicine, Assiut, Assiut, Egypt, ⁴Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁵Clinical Pathology Department, Aswan University Hospital, Aswan, Egypt
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in severe joint damage and physical disability, therefore, the discovery of new marker(s) for…
Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Regina Kurrasch⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Keio University School of Medicine, Tokyo, Japan, ³University of Toronto, Newmarket, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…
Abstract Number: 2448 • 2017 ACR/ARHP Annual Meeting
Increased Cumulative Exposure to Tumor Necrosis Factor Inhibitors Reduces Radiographic Progression in US Veterans with Rheumatoid Arthritis in Real World Clinical Practice
Grant Cannon¹, Alan R. Erickson², Chia-Chen Teng, MS¹, Tina Huynh¹, Sally W. Wade³, Bradley S. Stolshek⁴, David Collier⁵, Alex Mutebi⁶ and Brian C. Sauer, PhD¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Wade Outcomes Research and Consulting, Salt Lake City, UT, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Global Health Economics, Amgen Inc., Thousand Oaks, CA
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) have been proven to reduce progression of structural joint damage in rheumatoid arthritis (RA) in randomized clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].